Entry Into a Material Definitive Agreement. Merger Agreement On August 16, 2026, DocGo Inc., a Delaware corporation ("DocGo" or the "Company"), Ambulnz Holdings, LLC, a Delaware limited liability company and a wholly owned subsidiary of the Company ("Ambulnz"), HH Merger Sub, LLC, a Delaware limited liability company and a wholly owned subsidiary of Ambulnz ("MergerCo"), Hicuity Health, Inc., a Delaware corporation ("Hicuity"), Concord Innovation Fund II, LP, a Delaware limited partnership ("…

Results of Operations and Financial Condition. On August 17, 2026, the Company issued a press release announcing the Company’s earnings results for the quarter ended June 30, 2026 (the “Press Release”). The Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Report”). As previously announced, the Company will also hold a conference call and webcast at 5:00 p.m. Eastern Time on August 17, 2026 to discuss its earnings results for the quarter ended June 30, 2026…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On July 28, 2026, DocGo Inc. (the “Company”) received a letter from the Nasdaq Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that Nasdaq has granted the Company an additional 180 calendar days, or until January 25, 2027, to regain compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the “Minimum…

Regulation FD Disclosure. On June 26, 2026, the Board of Directors of DocGo Inc. (the “Company”) approved an extension of the expiration date of the Company’s current share repurchase program (“Repurchase Program”) from June 30, 2026 to December 31, 2026. As previously disclosed, pursuant to the Repurchase Program, the Company may purchase up to $26 million in shares of the Company’s common stock. Other than the extension of the program’s expiration date, no changes were made to the Repurchas…

Results of Operations and Financial Condition. On May 11, 2026, DocGo Inc. (the “Company”) issued a press release announcing the Company’s earnings results for the quarter ended March 31, 2026 (the “Press Release”). The Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Report”). As previously announced, the Company will also hold a conference call and webcast at 5:00 p.m. Eastern Time on May 11, 2026 to discuss its earnings results for the quarter ended Marc…

Director — Stephen K. Klasko, MD: Dr. Klasko stepped down from the Board due to a new healthcare leadership role.

Results of Operations and Financial Condition. On March 16, 2026, DocGo Inc. (the “Company”) issued a press release announcing the Company’s earnings results for the quarter and year ended December 31, 2025 (the “Press Release”). The Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Report”). As previously announced, the Company will also hold a conference call and webcast at 5:00 p.m. Eastern Time on March 16, 2026 to discuss its earnings results for the qu…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On January 26, 2026, DocGo Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based upon the closing bid price of the Company’s common stock, par value $0.0001 per share (“Common Stock”), from December 9, 2025 to January 23, 2026, the Company is not currently in com…

Regulation FD Disclosure. On December 12, 2025, the Board of Directors of DocGo Inc. (the “Company”) approved an extension of the expiration date of the Company’s current share repurchase program (“Repurchase Program”) from December 31, 2025 to June 30, 2026. As previously disclosed, pursuant to the Repurchase Program, the Company may purchase up to $26 million in shares of the Company’s common stock. Other than the extension of the program’s expiration date, no changes were made to the Repur…

Results of Operations and Financial Condition. On November 10, 2025, DocGo Inc. (the “Company”) issued a press release announcing the Company’s earnings results for the quarter ended September 30, 2025 (the “Press Release”). The Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Report”). As previously announced, the Company will also hold a conference call and webcast at 5:00 p.m. Eastern Time on November 10, 2025 to discuss its earnings results for the quar…

Entry into a Material Definitive Agreement On October 20, 2025, Ambulnz Holdings, LLC (the “Purchaser”), a Delaware limited liability company and wholly-owned subsidiary of DocGo Inc. (the “Company”), a Delaware corporation, entered into an Agreement and Plan of Merger (the “Merger Agreement”) with STMD Merger Company, LLC, a Delaware limited liability company (“MergerCo”), SteadyMD, Inc., a Delaware corporation (the “Acquired Company”), and Shareholder Representative Services LLC, a Colorado…

Regulation FD Disclosure. On October 20, 2025, the Company will issue a press release announcing entry into the Merger Agreement and completion of the acquisition of the Acquired Company pursuant to the Merger Agreement. The Company also announces that it will host a conference call and webcast tomorrow at 11:00 a.m. ET to discuss the Transaction. Conference call and webcast details are included below and will be included in the press release. A copy of the presentation to be used in connecti…

Entry Into a Material Definitive Agreement. On October 20, 2025, Ambulnz Holdings, LLC (the “Purchaser”), a Delaware limited liability company and wholly-owned subsidiary of DocGo Inc. (the “Company”), a Delaware corporation, entered into an Agreement and Plan of Merger (the “Merger Agreement”) with STMD Merger Company, LLC, a Delaware limited liability company (“MergerCo”), SteadyMD, Inc., a Delaware corporation (the “Acquired Company”), and Shareholder Representative Services LLC, a Colorad…

Results of Operations and Financial Condition. On August 7, 2025, DocGo Inc. (the “Company”) issued a press release announcing the Company’s earnings results for the quarter ended June 30, 2025 (the “Press Release”). The Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Report”). As previously announced, the Company will also hold a conference call and webcast at 5:00 p.m. Eastern Time on August 7, 2025 to discuss its earnings results for the quarter ended J…

Regulation FD Disclosure. On June 12, 2025, the Board of Directors of DocGo Inc. (the “Company”) approved an extension of the expiration date of the Company’s current share repurchase program (“Repurchase Program”) from June 30, 2025 to December 31, 2025. As previously disclosed, pursuant to the Repurchase Program, the Company may purchase up to $26 million in shares of the Company’s common stock. Other than the extension of the program’s expiration date, no changes were made to the Repurchas…

Results of Operations and Financial Condition. On May 8, 2025, DocGo Inc. (the “Company”) issued a press release announcing the Company’s earnings results for the quarter ended March 31, 2025 (the “Press Release”). The Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Report”). As previously announced, the Company will also hold a conference call and webcast at 5:00 p.m. Eastern Time on May 8, 2025 to discuss its earnings results for the quarter ended March…

Results of Operations and Financial Condition. On February 27, 2025, DocGo Inc. (the “Company”) issued a press release announcing the Company’s earnings results for the quarter and year ended December 31, 2024 (the “Press Release”). The Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Report”). As previously announced, the Company will also hold a conference call and webcast at 5:00 p.m. Eastern Time on February 27, 2025 to discuss its earnings results for…

Regulation FD Disclosure. On December 20, 2024, the Board of Directors of DocGo Inc. (the “Company”) approved an extension of the expiration date of the Company’s current share repurchase program (“Repurchase Program”) from December 31, 2024 to June 30, 2025. As previously disclosed, pursuant to the Repurchase Program, the Company may purchase up to $26 million in shares of the Company’s common stock. Other than the extension of the program’s expiration date, no changes were made to the Repur…

Results of Operations and Financial Condition. On November 7, 2024, DocGo Inc. (the “Company”) issued a press release announcing the Company’s earnings results for the quarter ended September 30, 2024 (the “Press Release”). The Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Report”). As previously announced, the Company will also hold a conference call and webcast at 5:00 p.m., Eastern Time, on November 7, 2024 to discuss its earnings results for the quar…

Chair of the Board — Stephen K. Klasko, MD: Dr. Klasko was appointed as the new independent Chair of the Board to fill the vacancy left by Steven Katz's resignation.

Results of Operations and Financial Condition. On August 7, 2024, DocGo Inc. (the “Company”) issued a press release announcing the Company’s earnings results for the quarter ended June 30, 2024 (the “Press Release”). The Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Report”). As previously announced, the Company will also hold a conference call and webcast at 5:00 p.m., Eastern Time, on August 7, 2024 to discuss its earnings results for the quarter ended…

Results of Operations and Financial Condition. On May 8, 2024, DocGo Inc. (the “Company”) issued a press release announcing the Company’s earnings results for the quarter ended March 31, 2024 (the “Press Release”). The Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Report”). The information in this Report and the Press Release is being furnished and shall not be deemed “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange…

Other Events. DocGo Inc. (the “Company”) recently identified a cybersecurity incident involving certain of the Company’s systems. Promptly after detecting unauthorized activity, the Company took steps to contain and respond to the incident, including launching an investigation, with assistance from leading third-party cybersecurity experts, and notifying relevant law enforcement. As part of its investigation, the Company has determined that the threat actor accessed and acquired data, includi…

Chair of the Board, Director — Stan Vashovsky: Stan Vashovsky retired as a director and Chair of the Board, succeeded by Steven Katz.

Results of Operations and Financial Condition. On February 28, 2024, DocGo Inc. (the “Company”) issued a press release announcing the Company’s earnings results for the quarter and year ended December 31, 2023 (the “Press Release”). The Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Report”). The information in this Report and the Press Release is being furnished and shall not be deemed “filed” for purposes of the Securities Exchange Act of 1934, as amend…